scholarly journals Dynamics of a Breast Cancer Model for Neutropenia Case due to Chemotherapy Effects

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
M. Ivan Ariful Fathoni ◽  
Fajar Adi-Kusumo ◽  
Gunardi Gunardi ◽  
Susanna Hilda Hutajulu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Interaction Model ◽  
Breast Cancer Case ◽  
The Body ◽  
Cancer Case ◽  
Dimensional System ◽  
Breast Cancer Patients ◽  
Dimensional Parameter ◽  
Chemotherapy Drugs

Breast cancer is a type of carcinoma with a high prevalence. The treatment of breast cancer through chemotherapy can cause a risk to healthy cells throughout the body. The neutrophil is one of the cells that is influenced by chemotherapy drugs. Chemotherapy-induced neutropenia is one of the most common toxic effects experienced by patients and often threatens chemotherapy to use efficiency. In this paper, we introduce an interaction model between blood components, i.e., neutrophil, lymphocytes, and albumin, with chemotherapy drugs. The model is important to understand the neutropenia effect due to chemotherapy in mathematical perspective and to calculate breast cancer patients’ survival level. Our model is a four-dimensional system of the first-order ODE with 13-dimensional parameter space. We focus our study for understanding the steady-state conditions and the bifurcations when the parameter values are varied. Here, we also study the role of albumin for reducing the neutropenia effects for breast cancer patients mathematically, where the results can be used as an alternative solution for treating neutropenia in a breast cancer case.

scholarly journals CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jennifer K. Lang ◽  
Badri Karthikeyan ◽  
Adolfo Quiñones-Lombraña ◽  
Rachael Hageman Blair ◽  
Amy P. Early ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Care Center ◽  
Left Ventricular ◽  
The Body ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Echocardiographic Parameters ◽  
The Impact

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity in adult cohorts. Objectives This study evaluated the presence of associations between CBR3 V244M genotype status and changes in echocardiographic parameters in breast cancer patients undergoing doxorubicin treatment. Methods We recruited 155 patients with breast cancer receiving treatment with doxorubicin (DOX) at Roswell Park Comprehensive Care Center (Buffalo, NY) to a prospective single arm observational pharmacogenetic study. Patients were genotyped for the CBR3 V244M variant. 92 patients received an echocardiogram at baseline (t0 month) and at 6 months (t6 months) of follow up after DOX treatment. Apical two-chamber and four-chamber echocardiographic images were used to calculate volumes and left ventricular ejection fraction (LVEF) using Simpson’s biplane rule by investigators blinded to all patient data. Volumetric indices were evaluated by normalizing the cardiac volumes to the body surface area (BSA). Results Breast cancer patients with CBR3 GG and AG genotypes both experienced a statistically significant reduction in LVEF at 6 months following initiation of DOX treatment for breast cancer compared with their pre-DOX baseline study. Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 months following DOX therapy in comparison with patients with heterozygous AG genotype. We found no differences in age, pre-existing cardiac diseases associated with myocardial injury, cumulative DOX dose, or concurrent use of cardioprotective medication between CBR3 genotype groups. Conclusions CBR3 V244M genotype status is associated with changes in echocardiographic parameters suggestive of early anthracycline-related cardiomyopathy in subjects undergoing chemotherapy for breast cancer.

scholarly journals HUBUNGAN ANTARA NAFSU MAKAN DENGAN ASUPAN ENERGI DAN PROTEIN PADA PASIEN KANKER PAYUDARA POST KEMOTERAPI[Correlation between Appetite with Energy and Protein Intake of Post Chemotherapy Breast Cancer Patients]

2019 ◽  
Vol 14 (2) ◽  
pp. 170
Author(s):  
Silviana Putri ◽  
Merryana Adriani ◽  
Yayuk Estuningsih
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Side Effect ◽  
Protein Intake ◽  
Pearson Correlation ◽  
Observational Research ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Chemotherapy Drugs ◽  
Pearson Correlation Test

Chemotherapy drugs used to kill or inhibit proliferation of cancer cell that are cytotoxic and causing side effect for breast cancer patients. The side effect of chemotherapy drugs is decreasing the appetite which causing decrease in energy and protein intake, and could affect nutritional status. This study aim to determine the relationship between appetite with energy and protein intake of post chemotherapy breast cancer patients. This research was an analytic observational research using cross sectional design and purposive sampling conducted at Dr. Ramelan Navy Hospital Surabaya with a sample size of 50 patients. Correlation between appetite with energy and protein intake were analyzed using Pearson correlation. The average of energy and protein intake were 976.3±304.2 kcal and 29.4±12.9 g. Pearson correlation test showed signifi cant correlation between appetite as chemoteraphy side effect with energy intake (p=0.000; r=-0.558) and protein intake (p=0.000; r=-0.504). Decreasing of appetite due to chemoterapy reduce the energy and protein intake of breast cancer patient. Patient are suggest to consume foods in small portion but often to maintain adequate energy and protein intake.

Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors

2020 ◽  
pp. 107815522096321
Author(s):  
Rashida Bibi ◽  
Saira Azhar ◽  
Ayesha Iqbal ◽  
Hajera Jabeen ◽  
Umm-e Kalsoom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Health Care Professionals ◽  
Potential Drug ◽  
Breast Cancer Patients ◽  
Medication Regimen ◽  
Cancer Data ◽  
Chemotherapy Drugs

Breast cancer patients use numerous medications, which include cytotoxic chemotherapy drugs, hormonal agents and supportive medication, so they are more vulnerable to potential adverse drug interactions. This study aimed to evaluate frequency, severity, clinical importance and risk factors responsible for the Drug-drug interactions (DDIs) in a cohort of patients suffering from breast cancer. Data was obtained from 150 patients in the oncology ward (both inpatient and outpatient) with a confirmed diagnosis of breast cancer and currently receiving standard breast cancer-directed treatment. The data was recorded into a pre-designed form specifically made for this study through individual patient interviews and by reviewing the detailed medical chart records of the patients. DDIs were identified by using drug interaction software such as Medscape mobile application and Micromedex version 2. The results of this study showed that all patients were female. The mean numbers of drugs that patients used were 7. Potential drug interactions were identified in 92% of the patients. When drug groups were overviewed, 32% of interactions were between anti neoplastic drugs, 62.9% interactions were between the anti neoplastic agent and supportive care drugs and 5% of them were between anti-cancer drugs and drugs used to treat comorbidities. Major DDIs were found in 62.2% of patients, 25.3% of DDIs were moderate and 12.4% were minor. The number of drugs, comorbid diseases, and selection of chemo protocols were the risk factors for drug interactions. Most of the DDIs found in breast cancer therapy may have adverse consequences on patient health and therapeutic outcomes. Therefore, health care professionals should review the medication regimen of patients with breast cancer before starting any chemotherapy treatment.

scholarly journals Aquaporin 1 promotes sensitivity of anthracycline chemotherapy in breast cancer by inhibiting β-catenin degradation to enhance TopoIIα activity

2020 ◽  
Vol 28 (1) ◽  
pp. 382-400
Author(s):  
Wei Chong ◽  
Huikun Zhang ◽  
Zhifang Guo ◽  
Limin Yang ◽  
Ying Shao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nuclear Translocation ◽  
Glycogen Synthase ◽  
Breast Cancer Mortality ◽  
High Sensitivity ◽  
Breast Cancer Patients ◽  
Chemotherapy Drugs ◽  
Aqp1 Expression ◽  
Anthracycline Chemotherapy

AbstractAnthracyclines are a class of conventional and commonly used frontline chemotherapy drugs to treat breast cancer. However, the anthracycline-based regimens can only reduce breast cancer mortality by 20–30%. Furthermore, there is no appropriate biomarker for predicting responses to this kind of chemotherapy currently. Here we report our findings that may fill this gap by showing the AQP1 (Aquaporin1) protein as a potential response predictor in the anthracycline chemotherapy. We showed that breast cancer patients with a high level of AQP1 expression who underwent the anthracycline treatment had a better clinical outcome relative to those with a low level of AQP1 expression. In the exploration of the underlying mechanisms, we found that the AQP1 and glycogen synthase kinase-3β (GSK3β) competitively interacted with the 12 armadillo repeats of β-catenin, followed by the inhibition of the β-catenin degradation that led to β-catenin’s accumulation in the cytoplasm and nuclear translocation. The nuclear β-catenin interacted with TopoIIα and enhanced TopoIIα’s activity, which resulted in a high sensitivity of breast cancer cells to anthracyclines. We also found, the miR-320a-3p can attenuate the anthracycline’s chemosensitivity by inhibiting the AQP1 expression. Taken together, our findings suggest the efficacy of AQP1 as a response predictor in the anthracycline chemotherapy. The application of our study includes, but is not limited to, facilitating screening of the most appropriate breast cancer patients (who have a high AQP1 expression) for better anthracycline chemotherapy and improved prognosis purposes.

scholarly journals Analysis of the Effect of Prognosis Factors for Breast Cancer

2020 ◽  
Author(s):  
Mrinal Deka ◽  
Dibyojyoti Bhattacharjee
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Tumour Size ◽  
Poverty Line ◽  
The Body ◽  
Research Centre ◽  
Breast Cancer Patients ◽  
Prognosis Factor ◽  
Regional Lymph Nodes

Abstract Background: The idea of Prognosis factor is based on the variables that can be used to assess the chance of recovery from a disease. It is also considered as the prior knowledge about any disease before treatment. The concept is applied to the cancer patients to get an idea of how cancer will affect the body and how it will respond to the therapies. Method: In this paper, selective prognostic factors (Age, Node and Tumour size) are analysed by logistic regression in patients who are suffering from Breast cancer based on data collected from Cachar Cancer Hospital and Research Centre, Silchar, Assam, India. Results: The study claims that there are 50.1 percent and 65.8 percent chance of remission of cancer for patients of age above 50 in case of breast cancer with below poverty line and above poverty line respectively. The present study has focused on this cut-off value of 2 cm as the determining prognostic factor in relation to tumour size. Thus, the chance of remission from cancer is 22.3 percent and 34.7 percent for below poverty line and above poverty line patients respectively, if tumour size is greater than 2 cm.It also endeavours to ascertain that there are 10.9 percent and 18.1 percent chances of remission of cancer, if the disease has metastasized to regional lymph nodes, with below poverty line and above poverty line respectively.Conclusion: The parameters viz. Tumour size and Node status, which measure the stage of the cancer patients, are significant prognostic factors that help in predicting tumour behaviour and survival outcomes for breast cancer patients.

scholarly journals Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports

2016 ◽  
Vol 9 (3) ◽  
pp. 586-592 ◽  
Author(s):  
Magdalena Meissner ◽  
Alfredo Addeo
Keyword(s):  
Breast Cancer ◽  
Case Reports ◽  
Breast Cancer Case ◽  
Intrathecal Methotrexate ◽  
Cancer Case ◽  
Carcinomatous Meningitis ◽  
Breast Cancer Patients ◽  
Similar Treatment ◽  
Craniospinal Radiotherapy ◽  
Sequential Combination

Introduction: Carcinomatous meningitis in breast cancer occurs as a complication in up to 5% of all cases. It is a very devastating diagnosis, with a median patient survival of about 3 months. Treatment is very controversial, and different modalities of treatment have been used but none of them show significant benefit for overall survival. Case Reports: We report 2 cases of carcinomatous meningitis in breast cancer patients. They received a similar treatment of a combination of intrathecal (IT) methotrexate followed by craniospinal radiotherapy. Both patients survived for many years after treatment and are in complete clinical and radiological remission. Conclusion: Meningeal metastasis from breast cancer can be very effectively treated with IT and/or systemic chemotherapy followed by craniospinal radiotherapy. Further studies are needed to determine the effectiveness of this sequential combination of chemotherapy with radiotherapy.

scholarly journals The Association of Serum IL-33 and sST2 with Breast Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Zhi-Ping Yang ◽  
Dan-Yan Ling ◽  
Yong-Hong Xie ◽  
Wan-Xin Wu ◽  
Jin-Rui Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Serum Levels ◽  
The Body ◽  
Breast Cancer Dataset ◽  
Breast Cancer Patients ◽  
Interleukin 33 ◽  
Factor C

Breast cancer is one of the most common malignant diseases in women. The main cause of death from breast cancer is its metastases at distant sites in the body. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and found overexpressed in various cancers. The aim of the present study was to explore the association of serum IL-33 and sST2 with breast cancer. Here, the serum levels of Interleukin-33 (IL-33) and sST2 were found significantly higher in breast cancer patients than in healthy volunteers. Serum levels of vascular endothelial growth factor (VEGF), metalloproteinase-11 (MMP-11), and platelet-derived growth factor-C (PDGF-C) were also greater in breast cancer patients compared to healthy volunteers. We found that serum levels of IL-33 or sST2 were positively correlated with the serum levels of VEGF, MMP-11, and PDGF-C. Moreover, breast cancer dataset downloaded from The Cancer Genome Atlas showed that patients with higher level of MMP-11 or PDGF-C expression had shorter survival time than those with lower level of these proteins. In conclusion, IL-33 and sST2 may serve as noninvasive diagnosis markers for breast cancer. IL-33 and sST2 were significantly associated with MMP-11 or PDGF-C which indicated poor prognosis of breast cancer patients.

scholarly journals Impact of BMI for clinical outcomes in Japanese breast cancer patients

2020 ◽  
Vol 50 (3) ◽  
pp. 230-240
Author(s):  
Naomi Gondo ◽  
Masataka Sawaki ◽  
Masaya Hattori ◽  
Akiyo Yoshimura ◽  
Haruru Kotani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Disease Free Survival ◽  
Overweight And Obesity ◽  
The Body ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Er Positive ◽  
The Impact

Abstract Objective The relationship between the body mass index (BMI) at the time of breast cancer diagnosis and the prognosis of breast cancer patients has not yet been clarified. We investigated the impact of obesity for clinical outcomes in Japanese breast cancer patients. Methods Women with primary breast cancer operated between 2002 and 2014 were identified. All patients are categorized into four groups according to BMI. The range of BMI is <18.5 kg/m2, from 18.5 to 24.9 kg/m2, 25 to 29.9 kg/m2, >30 kg/m2 in underweight, normal, overweight and obesity groups, respectively. The correlation between BMI and overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS) were statistically analyzed. Results From the database of our institution, we identified 3223 patients. The median follow-up period was 57 months (1–149). We categorized 2257 (70.0%), 318 (9.9%), 545 (16.9%) and 103 (3.2%) patients into normal, underweight, overweight obesity groups respectively. There were189 patients (5.9%) deaths due to breast cancer recurrence (137 patients) and other disease (52 patients). Obesity groups was significantly high compared with normal groups for OS (adjusted HR, 2.43; 95% CI, 1.38–4.28; P < 0.001), BCSS (adjusted HR, 2.73; 95% CI, 1.15–6.44; P = 0.02) and DFS (adjusted HR, 1.83; 95% CI, 1.11–3.02; P = 0.017) by multivariate analysis. Especially, OS (adjusted HR, 4.87; 95% CI, 2.15–11.04; P < 0.001), BCSS (adjusted HR, 4.51; 95% CI, 1.52–13.34; P < 0.001) and DFS (adjusted HR, 4.87; 95% CI, 1.02–4.89; P = 0.04) were statistically insignificant in postmenopausal ER-positive breast cancer patients. Conclusion Obesity might be risk factor for OS, BCSS and DFS, especially postmenopausal ER-positive women.

scholarly journals Evaluation of Drug Side Effects Chemotherapy on Quality of Life (QOL) Breast Cancer Patients at Hospital X in Jakarta

2019 ◽  
Vol 17 (1) ◽  
pp. 9
Author(s):  
Sondang Khairani ◽  
Sesilia A Keban ◽  
Meyke Afrianty
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Sampling Technique ◽  
Cancer Type ◽  
Drug Side Effects ◽  
Breast Cancer Patients ◽  
Chemotherapy Drugs

Breast cancer is the number one cancer type discovered at women in the world. Most causes are genetic factors and hormonal factors. One cancer treatments with chemotherapy. Chemotherapy drugs active in cells dividing and reproducing, but cells normally to be affected by chemotherapy and side effects from chemotherapy drugs affect quality of life. The aim of the study to evaluate side effects of chemotherapy drugs on the quality of life of breast cancer patients. Sampling technique observational prospective breast cancer patients with completed the chemotherapy cycle from September 2017 to April 2018 with descriptive analysis and statistics by looking correlation between drug side effects and Quality of Life (QoL). Results of the study were side effects of fatigue 100%, nausea 67,5%, vomiting 60%, no appetite 63,75%, fever 42,5%, joint pain 43,75%, diarrhea 16,25%, difficulty swallowing 16,25%, allergies 5%, itching 1,25%, mouth sores 3,75%, swollen right hand 1,25%, constipation 3,75%. QoL results are physical 6,2%; psychology 5,3%; social 4,9%; spiritual 6,8%. Results of Sperman test showed no correlation between the side effects of chemotherapy and QoL P> 0,05. This study shows that there is no relationship between the side effects drug chemotherapy and QoL in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document